Sara Ferrando-Martinez1, Rebeca S De Pablo-Bernal2, Marta De Luna-Romero2, Santiago J De Ory3, Miguel Genebat2, Yolanda M Pacheco2, Francisco J Parras4, Marta Montero5, Jose Ramón Blanco6, Felix Gutierrez7, Jesus Santos8, Francisco Vidal9, Richard A Koup1, María Ángeles Muñoz-Fernández3, Manuel Leal2, Ezequiel Ruiz-Mateos2. 1. Immunology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 2. Laboratory of Immunovirology, Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, Spain. 3. Molecular Immunobiology Laboratory, General University Hospital Gregorio Marañon, Health Research Institute Gregorio Marañon, Spanish HIV HGM BioBank, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, Madrid, Spain. 4. Infectious Disease Unit, General Universitary Hospital Gregorio Marañon, Madrid, Spain. 5. Infectious Disease Unit, Polytechnic and University Hospital La Fe, Valencia, Spain. 6. Infectious Diseases Department, Hospital San Pedro, Center for Biomedical Research of La Rioja, Logrono, Spain. 7. Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain. 8. Infectious Diseases Unit, Virgen de la Victoria University Hospital, Instituto de Investigación Biomédica de Málaga, Spain. 9. Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Spain.
Abstract
Background: Thymic function has been mainly analyzed with surrogate peripheral markers affected by peripheral T-cell expansion, making it difficult to assess the role of thymic failure in human immunodeficiency virus (HIV) disease progression. The assay of signal-joint/DβJβ T-cell rearrangement excision circles (sj/β-TREC ratio) overcomes this limitation but has only been assayed in small cohorts. Thus, the aim of this study was to determine the role of thymic function, measured by the sj/β-TREC ratio, on CD4 T-cell maintenance in prospective HIV cohorts that include patients with a wide age range and different immunological phenotypes. Methods: Seven hundred seventy-four patients including typical progressors, long-term nonprogressors (LTNPs), and vertically HIV-infected subjects were analyzed. Thymic function was quantified in peripheral blood samples using the sj/β-TREC ratio. Associations between thymic function and CD4 T-cell dynamics and combination antiretroviral therapy (cART) onset were analyzed using linear, logistic, and Cox proportional hazard models. Results: Thymic function failure (sj/β-TREC ratio <10) was independently associated with HIV progression. In agreement, patients with distinctive high CD4 T-cell levels and low progression rates (vertically HIV-infected patients and LTNPs, including HIV controllers) had significantly higher thymic function levels whereas patients with thymic function failure had lower CD4 T-cell levels, lower nadir, and faster CD4 T-cell decay. Conclusions: This work establishes the relevance of thymic function, measured by sj/β-TREC ratio, in HIV disease progression by analyzing a large number of patients in 3 cohorts with different HIV disease progression phenotypes. These results support and help to understand the mechanisms underlying the rationale of early cART onset.
Background: Thymic function has been mainly analyzed with surrogate peripheral markers affected by peripheral T-cell expansion, making it difficult to assess the role of thymic failure in human immunodeficiency virus (HIV) disease progression. The assay of signal-joint/DβJβ T-cell rearrangement excision circles (sj/β-TREC ratio) overcomes this limitation but has only been assayed in small cohorts. Thus, the aim of this study was to determine the role of thymic function, measured by the sj/β-TREC ratio, on CD4 T-cell maintenance in prospective HIV cohorts that include patients with a wide age range and different immunological phenotypes. Methods: Seven hundred seventy-four patients including typical progressors, long-term nonprogressors (LTNPs), and vertically HIV-infected subjects were analyzed. Thymic function was quantified in peripheral blood samples using the sj/β-TREC ratio. Associations between thymic function and CD4 T-cell dynamics and combination antiretroviral therapy (cART) onset were analyzed using linear, logistic, and Cox proportional hazard models. Results: Thymic function failure (sj/β-TREC ratio <10) was independently associated with HIV progression. In agreement, patients with distinctive high CD4 T-cell levels and low progression rates (vertically HIV-infectedpatients and LTNPs, including HIV controllers) had significantly higher thymic function levels whereas patients with thymic function failure had lower CD4 T-cell levels, lower nadir, and faster CD4 T-cell decay. Conclusions: This work establishes the relevance of thymic function, measured by sj/β-TREC ratio, in HIV disease progression by analyzing a large number of patients in 3 cohorts with different HIV disease progression phenotypes. These results support and help to understand the mechanisms underlying the rationale of early cART onset.
Authors: Yue Yang; Maha Al-Mozaini; Maria J Buzon; Jill Beamon; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos; Eric S Rosenberg; Florencia Pereyra; Xu G Yu; Mathias Lichterfeld Journal: AIDS Date: 2012-03-27 Impact factor: 4.177
Authors: Sara Ferrando-Martínez; Ezequiel Ruiz-Mateos; Jarrod A Dudakov; Enrico Velardi; Johannes Grillari; David P Kreil; M Ángeles Muñoz-Fernandez; Marcel R M van den Brink; Manuel Leal Journal: J Gerontol A Biol Sci Med Sci Date: 2014-03-22 Impact factor: 6.053
Authors: Sara Ferrando-Martínez; Jaime M Franco; Ezequiel Ruiz-Mateos; Ana Hernández; Antonio Ordoñez; Encarnación Gutierrez; Manuel Leal Journal: J Immunol Methods Date: 2009-11-15 Impact factor: 2.303
Authors: Ramia Zakhour; Dat Q Tran; Guenet Degaffe; Cynthia S Bell; Elizabeth Donnachie; Weihe Zhang; Norma Pérez; Laura J Benjamins; Gabriela Del Bianco; Gilhen Rodriguez; James R Murphy; Gloria P Heresi Journal: Clin Infect Dis Date: 2016-02-21 Impact factor: 9.079
Authors: M D Hazenberg; S A Otto; J W Cohen Stuart; M C Verschuren; J C Borleffs; C A Boucher; R A Coutinho; J M Lange; T F Rinke de Wit; A Tsegaye; J J van Dongen; D Hamann; R J de Boer; F Miedema Journal: Nat Med Date: 2000-09 Impact factor: 53.440
Authors: Sonia Molina-Pinelo; Alejandro Vallejo; Laura Díaz; Natalia Soriano-Sarabia; Sara Ferrando-Martínez; Salvador Resino; María Angeles Muñoz-Fernández; Manuel Leal Journal: J Antimicrob Chemother Date: 2009-07-16 Impact factor: 5.790
Authors: E Ruiz-Mateos; A Rubio; A Vallejo; R De la Rosa; A Sanchez-Quijano; E Lissen; M Leal Journal: Clin Exp Immunol Date: 2004-06 Impact factor: 4.330
Authors: D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup Journal: Nature Date: 1998-12-17 Impact factor: 49.962
Authors: Ma Isabel de Jose; Santiago Jiménez de Ory; Maria Espiau; Claudia Fortuny; Ma Luisa Navarro; Pere Soler-Palacín; Ma Angeles Muñoz-Fernandez Journal: BMC Infect Dis Date: 2013-01-02 Impact factor: 3.090
Authors: M Leal; Y M Pacheco; I Herrero-Fernández; I Rosado-Sánchez; A I Álvarez-Ríos; M I Galvá; M De Luna-Romero; S Sanbonmatsu-Gámez; M Pérez-Ruiz; J M Navarro-Marí; A Carrillo-Vico; B Sánchez; R Ramos; J Cañizares Journal: Immun Ageing Date: 2019-07-05 Impact factor: 6.400
Authors: Annalisa Dalzini; Giovanni Ballin; Sara Dominguez-Rodriguez; Pablo Rojo; Maria Raffaella Petrara; Caroline Foster; Nicola Cotugno; Alessandra Ruggiero; Eleni Nastouli; Nigel Klein; Stefano Rinaldi; Savita Pahwa; Paolo Rossi; Carlo Giaquinto; Paolo Palma; Anita De Rossi Journal: J Int AIDS Soc Date: 2021-11 Impact factor: 5.396